Section 182-52-0035 - Prescription drug affordability board-Review of drug prices(1) By June 30th of each year, using data considered relevant by the board, the board must identify legend drugs and biologics that:(a) Have been on the market for at least seven years;(b) Are dispensed at a retail, specialty, or mail-order pharmacy; and(c) Are not designated by the FDA under 21 U.S.C. Sec. 360bb as a drug solely for the treatment of a rare disease or condition.(2) The legend drugs and biologics must meet the following thresholds: (a) Brand name drugs and biologic products that must have: (i) A wholesale acquisition cost of $60,000 or more per year or course of treatment lasting less than 12 months; or(ii) A wholesale acquisition cost increase of 15 percent or more in any 12-month period or for a course of treatment lasting less than 12 months, or a 50 percent cumulative increase during any 36-month period.(b) A biosimilar product with an initial wholesale acquisition cost that is less than 15 percent lower than the wholesale acquisition cost of the reference biological product, on the date the biosimilar becomes available on the market; and(c) Generic drugs with a wholesale acquisition cost of $100 or more, for a 30-day supply or course of treatment less than 30 days, that has an increase in price of 200 percent or more in the preceding 12 months.Wash. Admin. Code § 182-52-0035
Adopted by WSR 24-02-078, Filed 1/2/2024, effective 6/10/2024